Author

Julia Frede

Dana-Farber Cancer InstituteORCID 0000-0002-4380-9673Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Martin L. SosiD· 2 shared Alena HeimsoethiD· 1 shared Alexander QuaasiD· 1 shared Amy Guillaumet-AdkinsiD· 1 shared Andrew E. PlaceiD· 1 shared Aubry K. MilleriD· 1 shared Ayla E. SchwäbeiD· 1 shared Bikash AdhikariiD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Martin L. SosORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MYC-MIZ1 Complexes at Enhancers Tune Neuroendocrine Identity of Small Cell Lung Cancer

Lisa Marie Fröhlich, Hannah Lea Tumbrink, Bikash Adhikari, Margarita Rempe, Jenny Ostendorp, Paula Zickler, Michaela Nicole Hoehne, Alena Heimsoeth, Yichun Tang, Stefanie Lennartz, Ayla E. Schwäbe, Lisa Werr, Matthias Fischer, Alexander Quaas, Holger Gruell, , Martin L. Sos

This study identifies Miz1/Myc complexes at enhancers as key regulators of neuroendocrine identity in SCLC, showing their role in gene expression and chemosensitivity.

bioRxiv · Aug 20, 2026 · PreprintCancer Biology

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy

Jana Samarin, Hana Nůsková, Piotr Fabrowski, Mona Malz, Eberhard Amtmann, Minerva Taubert, Daniel Pastor‐Flores, Daniel N. Kazdal, Roman Kurilov, Nicole de Vries, Hannelore Pink, Frank H. Deis, Johanna Hummel-Eisenbeiss, Lisa Renz, Kamini Kaushal, , Nikolas Gunkel

The paper shows that activating the NRF2 pathway can safely increase the dose of TXNRD1 inhibitors in SCLC treatment without harming healthy tissues.

Nature Communications · Apr 11, 2026Peer-reviewedCancer Biology

Altered immune and treatment response gene expression signatures among poverty-exposed children with B-ALL

Amy Guillaumet-Adkins, Noori Sotudeh, Sayalee V. Potdar, Tushara Vijaykumar, Monica S. Nair, Valeriya Dimitrova, Julia Frede, Yana Pikman, Marian H. Harris, Andrew E. Place, Lewis B. Silverman, Jens G. Lohr, Kira O'Neil Bona, Birgit Knoechel

This study identifies transcriptional signatures of steroid resistance and altered immune responses in poverty-exposed children with B-ALL using single-cell RNA sequencing.

bioRxiv · Jan 29, 2026 · PreprintCancer Biology